02064nam a22003734a 4500001001200000003000800012006001900020007001500039008004100054010001700095016002000112020002300132020002600155040002100181035002100202050002300223082002000246100002100266245019500287260004800482300002700530504006400557505058400621533015201205650003101357650003101388650003401419650002801453655002901481700002001510710001701530856012601547999001701673ebr10275622CaPaEBRm        u        cr cn|||||||||080527s2009    njua    sb    001 0 eng    z  20080228077 z1014749212DNLM  z0470229640 (cloth)  z9780470229644 (cloth)  aCaPaEBRcCaPaEBR  a(OCoLC)31748352414aRC677b.T87 2009eb04a616.1/230612221 aTurner, J. Rick.10aIntegrated cardiac safetyh[electronic resource] :bassessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance /cJ. Rick Turner, Todd A. Durham.  aHoboken, N.J. :bJohn Wiley & Sons,cc2009.  axxviii, 470 p. :bill.  aIncludes bibliographical references (p. 397-455) and index.0 aThe importance of cardiac safety assessments -- The biological basis of adverse drug reactions -- Cardiac structure and function -- Cardiac pathophysiology and disease -- Drug discovery and drug design -- Nonclinical development -- The thorough QT/QTc trial -- General safety assessments -- Therapeutic use trials and meta-analyses -- Assessment methodologies in nonexperimental postmarketing surveillance -- Postmarketing proarrhythmic cardiac safety assessments -- Generalized cardiac safety -- Medication errors, adherence, and concordance -- Future directions in drug safety.  aElectronic reproduction.bPalo Alto, Calif. :cebrary,d2013.nAvailable via World Wide Web.nAccess may be limited to ebrary affiliated libraries. 0aCardiovascular toxicology. 0aHeartxEffect of drugs on. 0aDrugsxSide effectsxTesting. 0aDrugsxSafety measures. 7aElectronic books.2local1 aDurham, Todd A.2 aebrary, Inc.40uhttp://site.ebrary.com/lib/rucke/Doc?id=10275622zAn electronic book accessible through the World Wide Web; click to view  c20835d20835